Discovery of aminoglycoside mimetics by NMR-based screening of Escherichia coli A-site RNA. Yu L, Oost TK, Schkeryantz JM, Yang J, Janowick D, Fesik SW (2003) J Am Chem Soc 125: 4444-50 Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Carter TA, Wodicka LM, Shah NP, Velasco AM, Fabian MA, Treiber DK, Milanov ZV, Atteridge CE, Biggs WH, Edeen PT, Floyd M, Ford JM, Grotzfeld RM, Herrgard S, Insko DE, Mehta SA, Patel HK, Pao W, Sawyers CL, Varmus H, Zarrinkar PP, Lockhart DJ (2005) Proc Natl Acad Sci U S A 102: 11011-6 Apoptotic response of HL-60 human leukemia cells to the antitumor drug TAS-103. Kluza J, Lansiaux A, Wattez N, Mahieu C, Osheroff N, Bailly C (2000) Cancer Res 60: 4077-84 Base-displaced intercalation of the 2-amino-3-methylimidazo[4,5-f]quinolone N2-dG adduct in the NarI DNA recognition sequence. Stavros KM, Hawkins EK, Rizzo CJ, Stone MP (2014) Nucleic Acids Res 42: 3450-63 Calcium-activated and voltage-gated potassium channels of the pancreatic islet impart distinct and complementary roles during secretagogue induced electrical responses. Jacobson DA, Mendez F, Thompson M, Torres J, Cochet O, Philipson LH (2010) J Physiol 588: 3525-37 The epidermal growth factor receptor as a target for colorectal cancer therapy. Lockhart AC, Lockhart C, Berlin JD (2005) Semin Oncol 32: 52-60 DNA topoisomerases as targets for the anticancer drug TAS-103: primary cellular target and DNA cleavage enhancement. Byl JA, Fortune JM, Burden DA, Nitiss JL, Utsugi T, Yamada Y, Osheroff N (1999) Biochemistry 38: 15573-9 DNA topoisomerases as targets for the anticancer drug TAS-103: DNA interactions and topoisomerase catalytic inhibition. Fortune JM, Velea L, Graves DE, Utsugi T, Yamada Y, Osheroff N (1999) Biochemistry 38: 15580-6 A note on the use of Quin2 in studying shear-induced platelet aggregation. Giorgio TD, Hellums JD (1986) Thromb Res 41: 353-9
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.